Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma

BMC Cancer

Table 1 Patient characteristics

Variables		Patients with ECP high^a (n = 34)		Patients with ECP low^b (n = 22)		p-value
Age	Median (Range)	60 years (40–83 years)		64 years (31–90 years)		0.3877
OS	Median (Range)	12 months (2–48 months)		28 months (3–44 months)		0.0916
		n	%	n	%
Gender	Male	22	65	14	64	0.9350
Gender	Female	12	35	8	36	0.9350
Therapy	Surgery	31	91	19	86	0.6701
	Interferon-alpha	13	38	7	32	0.6245
	Chemotherapy	29	85	13	59	0.0270
	Radiotherapy	25	74	17	77	0.7520
	Signal transduction inhibitor (targeted therapy)	21	62	9	41	0.1264
	Checkpoint inhibitor therapy (immunotherapy)	9	26	18	82	< 0.0001
Type of melanoma	Cutaneous	20^c	59	12	55	0.7520
	MUP	5	15	9	41	0.0270
	Uveal	3	9	1	5	> 0.9999
	Mucosal	7^c	21	0	0	0.0349
LDH	> ULN	20	59	18	82	0.0868
LDH	< ULN	14	41	4	18	0.0868
BRAF status^d	V600 mutation	13	38	9^e	41	0.7151
BRAF status^d	V600 wildtype	14	41	12^e	55	0.7151
Brain metastases (M1d)		18	53	8	36	0.2244

^adefined as > 16.0 ng/ml
^bdefined as < 16.0 ng/ml
^cone patient has both, cutaneous and mucosal melanoma
^dBRAF status of 7 patients was not tested, BRAF test result of one patient was not evaluable
^eone patient has discrepant test results of two distinct metastases one with V600E mutation and one with wildtype

ISSN: 1471-2407